UBS Downgrades QuidelOrtho to Sell, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
UBS analyst John Sourbeer downgraded QuidelOrtho (NASDAQ:QDEL) from Neutral to Sell and reduced the price target from $70 to $42, indicating a bearish outlook on the stock.

March 04, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS downgraded QuidelOrtho from Neutral to Sell and lowered the price target from $70 to $42.
The downgrade from Neutral to Sell by a major analyst like UBS, accompanied by a significant reduction in the price target, suggests a bearish outlook for QuidelOrtho. This is likely due to underlying concerns about the company's future performance or market conditions affecting its sector. Such a downgrade can lead to a negative perception among investors, potentially causing a short-term decline in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100